Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...

Back in May, health data company Datavant announced its plans to acquire Aetion, creating a formidable player in the ...

This pricing shock immediately exposed pharma’s second crisis: R&D costs that continue to climb, now between $0.8 and $2.8 ...

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from ...

Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint ...